These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33103454)

  • 1. GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice.
    Lu Z; Li Y; Syn WK; Li AJ; Ritter WS; Wank SA; Lopes-Virella MF; Huang Y
    Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E30-E42. PubMed ID: 33103454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of GPR40 in LDL receptor-deficient mice exacerbates high-fat diet-induced hyperlipidemia and nonalcoholic steatohepatitis.
    Lu Z; Li Y; Li AJ; Syn WK; Wank SA; Lopes-Virella MF; Huang Y
    PLoS One; 2022; 17(11):e0277251. PubMed ID: 36331958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36.
    Zhu H; Zhao T; Zhao S; Yang S; Jiang K; Li S; Kang Y; Yang Z; Shen J; Shen S; Tao H; Xuan J; Yang M; Xu B; Wang F; Jiang M
    Metabolism; 2024 Jul; 156():155914. PubMed ID: 38642829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.
    Wilson CG; Tran JL; Erion DM; Vera NB; Febbraio M; Weiss EJ
    Endocrinology; 2016 Feb; 157(2):570-85. PubMed ID: 26650570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice.
    Gruben N; Aparicio Vergara M; Kloosterhuis NJ; van der Molen H; Stoelwinder S; Youssef S; de Bruin A; Delsing DJ; Kuivenhoven JA; van de Sluis B; Hofker MH; Koonen DP
    PLoS One; 2014; 9(4):e96345. PubMed ID: 24781986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
    Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
    Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease.
    Sheedfar F; Sung MM; Aparicio-Vergara M; Kloosterhuis NJ; Miquilena-Colina ME; Vargas-Castrillón J; Febbraio M; Jacobs RL; de Bruin A; Vinciguerra M; García-Monzón C; Hofker MH; Dyck JR; Koonen DP
    Aging (Albany NY); 2014 Apr; 6(4):281-95. PubMed ID: 24751397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
    Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
    Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
    Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.
    Zhang H; Li Y; Zhang C; Huang K; Zhao J; Le S; Jiang L; Liu H; Yang P; Xiao X; Yu J; Wu J; Ye P; Xia J
    Cell Death Dis; 2022 Apr; 13(4):359. PubMed ID: 35436984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.
    Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C
    PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
    Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
    J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease.
    Li DJ; Liu J; Hua X; Fu H; Huang F; Fei YB; Lu WJ; Shen FM; Wang P
    Metabolism; 2018 Feb; 79():52-63. PubMed ID: 29129819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
    Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
    J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipogenic changes of hepatocytes in a high-fat diet-induced fatty liver mice model and non-alcoholic fatty liver disease patients.
    Pan X; Wang P; Luo J; Wang Z; Song Y; Ye J; Hou X
    Endocrine; 2015 Apr; 48(3):834-47. PubMed ID: 25138963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight.
    Ookawara M; Matsuda K; Watanabe M; Moritoh Y
    J Pharmacol Exp Ther; 2020 Oct; 375(1):21-27. PubMed ID: 32719069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.